Why Halozyme Therapeutics, Inc. (HALO) Stock Rose 20.2% on Aug 7, 2026
The clearest new catalyst: Record Q2 2026 results, released after Thursday's close.
Why did HALO stock rise?
Halozyme Therapeutics shares surged 20.24% on August 7, 2026, after the company reported record Q2 2026 results — released after Thursday's close — with revenue up 48% to $481 million, well ahead of consensus, and raised full-year 2026 guidance. A wave of same-day analyst price-target increases, including an upgrade from Leerink, reinforced the move.
- Record Q2 2026 results, released after Thursday's close: Halozyme released results at 4:01 p.m. ET on August 6 (after the close), with a call at 4:30 p.m. ET. Total revenue was $481.0 million (+48% YoY) and royalty revenue was $307.7 million (+50% YoY), both GAAP figures, roughly 20% above the ~$402 million FactSet consensus cited by Investor's Business Daily. GAAP diluted EPS was $1.90; non-GAAP EPS was $2.28.
- Raised full-year 2026 guidance: Halozyme raised full-year 2026 total-revenue guidance to $1.835-$1.910 billion (from $1.710-$1.810 billion) and lifted royalty-revenue, adjusted-EBITDA and non-GAAP EPS guidance as well.
- Wave of same-day analyst price-target increases: On August 7, Morgan Stanley raised its target to $105 (from $93), TD Cowen to $105 (from $96), Wells Fargo to $95 (from $75), Citizens to $93 (from $92) and H.C. Wainwright to $115 (from $95); Leerink upgraded HALO to Outperform from Market Perform with a $110 target (from $83) — the most substantive rating change of the group.
How the story developed
- August 6, 2026 (4:01 p.m. ET)Halozyme released Q2 2026 results after the close; call followed at 4:30 p.m. ET.
- August 7, 2026HALO opened at $90.00 (a roughly 4.9% gap up) and climbed through the session to close at $103.12, up 20.24%.
- August 7, 2026Six analysts raised price targets or ratings through the day, led by Leerink's upgrade to Outperform.
What it could mean for HALO investors
The constructive case
- Royalty revenue grew 50% YoY, underscoring the durability of Halozyme's ENHANZE licensing model.
- Guidance was raised meaningfully, not just reaffirmed, and Leerink's upgrade reflects growing confidence in long-term ENHANZE durability.
The cautious case & what could invalidate it
- At $103.12, HALO had already reached roughly the average of the six newly published analyst targets (~$103.83) — the rally largely caught up with the reset target range in a single session, leaving less obvious room for further re-rating absent new news.
- A miss on the next print or a slowdown in new licensing deals could unwind some of the move.
Initial detection
BestStocks first flagged HALO intraday on Aug 7, 2026; this analysis was finalized after the close using the confirmed +20.2% session move and additional catalyst research.
Show the initial intraday note
Halozyme Therapeutics, Inc. (HALO) moved +13.94% from $90.50 to $103.12 on 2026-08-07, reaching a new 30-day high. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
What to watch next: Watch for upcoming earnings announcements or any press releases that might explain the rally and establish support at these higher levels.
Frequently asked questions
Why did Halozyme Therapeutics, Inc. (HALO) stock rise on Aug 7, 2026?
Halozyme Therapeutics shares surged 20.24% on August 7, 2026, after the company reported record Q2 2026 results — released after Thursday's close — with revenue up 48% to $481 million, well ahead of consensus, and raised full-year 2026 guidance. A wave of same-day analyst price-target increases, including an upgrade from Leerink, reinforced the move.
How much did HALO stock rise on Aug 7, 2026?
HALO rose 20.2% during the Aug 7, 2026 trading session.
What were the main drivers behind HALO's move?
Record Q2 2026 results, released after Thursday's close; Raised full-year 2026 guidance; Wave of same-day analyst price-target increases.